ArticleTherapeutic advances in psychopharmacology2016
Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.
Article in Therapeutic advances in psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04197037 (Prevalence Study of Sialorrhea in Inpatients and Outpatients Treated With Clozapine), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence Study of Sialorrhea in Inpatients and Outpatients Treated With Clozapine
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.CNS drugs · 2022Guideline
- Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis.CNS drugs · 2019Pooled it
- Feasibility and structure of a state hospital botulinum neurotoxin clinic for clozapine-induced sialorrhea.Annals of general psychiatry · 2025Article
- Oral Adverse Effects of Antipsychotic Medications: A Case/Noncase Analysis of EudraVigilance Data.Oral diseases · 2025Article
- Oral Health in Individuals with Severe Mental Illness on Second-Generation Antipsychotics-A Scoping Review.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Article
- The mechanism of action of clozapine.Journal of psychopharmacology (Oxford, England) · 2025Article
- Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN).Schizophrenia (Heidelberg, Germany) · 2025Article
- Off-label Prescribing of Clozapine and Safety.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025Review
- On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.CNS drugs · 2024Article
- Article
- [Safety aspects during treatment with clozapine: : Adverse effects, titration, and therapeutic drug monitoring - a narrative review].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2023Review
- Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support.Pharmacy (Basel, Switzerland) · 2023Article
- Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study.BJPsych open · 2023Article
- Seventy Years of Antipsychotic Development: A Critical Review.Biomedicines · 2023Review
- Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.Therapeutic advances in psychopharmacology · 2023Review
- Sociodemographic characteristics and health-related quality of life of individuals undergoing antidepressant therapy.Scientific reports · 2022Article
- The impact of COVID-19 on a cohort of patients treated with clozapine.Irish journal of psychological medicine · 2021Article
- Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation".Clinical pharmacokinetics · 2021Article
- Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation.Clinical pharmacokinetics · 2021Article
- Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with Schizophrenia: A Pilot Study.Translational neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study was to evaluate the prevalence and severity of clozapine-induced hypersalivation, and assess the impact hypersalivation has on global functioning.
methodsParticipants attending a dedicated clozapine clinic were invited to undertake a structured interview regarding their experiences of clozapine-induced hypersalivation. Two psychometric instruments to measure hypersalivation, the Nocturnal Hypersalivation Rating Scale and the Drooling Severity and Frequency Scale were used.
resultsClozapine-induced hypersalivation was experienced by 92% of participants, with nocturnal hypersalivation more prevalent compared to daytime hypersalivation (85% versus 48%). Daytime drooling was severe in 18% of cases and was present on a frequent or constant basis for 20% of individuals. Hypersalivation had at least a moderate impact on the quality of life of 15% of study participants.
conclusionsClozapine-induced hypersalivation is the most prevalent adverse effect experienced by patients treated with clozapine and negatively impacts on quality of life, particularly if daytime drooling is present. The development of further strategies to ameliorate this adverse effect is required given the demonstrated lack of success to date in managing this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.